Noteworthy, CAF-derived TGFβ may contribute to immunosurveillance and escape and may participate in therapy resistance, including immunotherapy with immune checkpoint blockade [83,84,85], also by excluding CD8+ T lymphocytes from the tumor site [86,87]. Here, TGFB1 is linked to neoplasm.